Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Allen C. Ho, MD, director of retina research at Wills Eye Hospital, said 2026 is going to be a “really big year” in retina.
According to Ho, topline results are expected for tyrosine kinase inhibitors from EyePoint Pharmaceuticals and Ocular Therapeutix. Results are also expected on subretinal gene therapy from AbbVie and Regenxbio on sura-vec for biofactory production of anti-VEGF therapy for neovascular age-related macular degeneration.
“I’m looking forward to these potential management-changing